[search1]
[search1]

Using its proprietary high throughput screening (HTS) FCS+plus technology, Evotec is able offer screening for biochemical or functional responses using its own 250,000 screening library or client's library of compounds. The benefits of using Evotec's screening technology include:

  • Superior detection technology
  • Assay miniaturization
  • Assay sensitivity
  • Multiple readout parameters

Using its proprietary readout technology, Evotec also offers a high throughput fragment screening capability that is capable of reliably detecting weak binders at very high concentrations.

Select an Assay Development & Screening Service

Track Record

  • More than 200 assays developed with over 50% run in HTS over the last 5 years
  • Vast experience with all major target classes including GPCR's, kinases, ion channels and proteases
  • Specific hits with IC50 below 25 µM identified for all major target classes
  • Specific hits with IC50 below 1 µM identified for most target classes
  • More than 20 lead compounds identified
  • More than 10 preclinical candidates derived from HTS hits
  • More than 100 HTS projects completed for over 30 Pharmaceutical and Biotechnology partners

Boehringer Ingelheim

"Evotec has a strong track record in performing uHTS screens and handling large compound pools in complex assays. Evotec's proprietary detection technology also offers sensitive and robust systems for hit identification."

Professor Mikael Dolsten, Head of Corporate Division Pharma Research/Discovery, Boehringer Ingelheim GmbH

[search2]
[search2]
[search3]
[search3]